A skin-moisturizing and barrier-maintaining composition containing S-estradiol, reduced coenzyme Q10, and ceramides.

By constructing a lipid complex matrix and using a stepwise diffusion mixing technology, the problems of uniformity and stability of active ingredients in existing nutritional compositions have been solved, achieving uniform dispersion and stability of S-estrol, reduced coenzyme Q10 and ceramide, which are suitable for solid food processing.

CN123100820APending Publication Date: 2026-11-17SUZHOU JIANLIDA NUTRITION TECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611450509.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-09-18
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing nutritional compositions suffer from several problems: limited variety of active ingredients, insufficient uniformity of low-addition components in solid powder systems, high fat solubility of reduced coenzyme Q10 making it difficult to maintain stability during processing and storage, and difficulty in balancing dispersion stability and compatibility with solid food processing after compounding multiple active ingredients.

Method used

This product utilizes a skin-nourishing and barrier-maintaining composition containing S-estradiol, reduced coenzyme Q10, and ceramides. By constructing a lipid complex matrix, including a starch matrix, β-cyclodextrin, trehalose, a lipid surface phase, and a sodium caseinate interfacial phase, and combining a stepwise diffusion mixing and nitrogen protection preparation method, the product ensures uniform dispersion and stability of the ingredients.

Benefits of technology

This study achieved uniform distribution of low-dose S-estrol, stable state of reduced coenzyme Q10, and suitability of the composition for solid food processing, thereby improving the stability and uniformity of the composition during storage and processing.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123100820A_ABST
    Figure CN123100820A_ABST
Patent Text Reader

Abstract

This invention discloses a skin-moisturizing and barrier-maintaining composition containing S-equorol, reduced coenzyme Q10, and ceramides, and its preparation method, relating to the field of nutritional food technology. The composition includes S-equorol, reduced coenzyme Q10, concentrated Pleurotus ostreatus powder, a lipid complex matrix, a solid filler, a dextrin-based carrier, an inorganic anti-caking agent, and a flavoring agent. The lipid complex matrix is ​​prepared from high-amylose corn starch, β-cyclodextrin, sodium caseinate, defatted sunflower seed phospholipids, glyceryl monostearate, and trehalose. Through stepwise premixing and lipid complex matrix loading, the distribution of low-dose components, the dispersion and stability of reduced coenzyme Q10, and the powder processing compatibility are improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of nutritional food technology, specifically to a skin-moisturizing and barrier-maintaining composition containing S-estradiol, reduced coenzyme Q10, and ceramides. Background Technology

[0002] The reproductive years before menopause are characterized by prolonged physiological cycle fluctuations. Factors such as lifestyle, stress, and aging can cause fluctuations in skin hydration, elasticity, and barrier function. Therefore, nutritional products need to address both skin appearance maintenance and barrier nutrition support. S-Estradiol is an active metabolite formed from the isoflavone daidzein of soybeans through intestinal flora metabolism. It exhibits selective affinity for estrogen receptor β, but the ability of the human body to convert daidzein into estradiol varies among individuals. Reduced coenzyme Q10 participates in mitochondrial electron transport and possesses lipid-soluble antioxidant properties. Ceramides are important components of stratum corneum lipids, related to skin hydration and barrier integrity; glucosylceramides have also been reported in *Pleurotus ostreatus*. Existing nutritional or oral skin-care compositions often focus on a single nutrient. When S-Estradiol, reduced coenzyme Q10, and ceramide-derived ingredients are incorporated into the same solid food system, there are still issues with formulation and processing compatibility. S-Estradiol, with its low single-use dosage, is prone to localized content differences when directly mixed with large proportions of powder excipients. Reduced Coenzyme Q10 is highly hydrophobic, limiting its dispersion in conventional dry powder systems, and its reduced state may transform into its oxidized state upon contact with air. Pleurotus ostreatus concentrate powder needs to be added quantitatively according to its ceramide content. The key technical challenge for this type of composition is how to design a suitable combination of these three components within an appropriate dosage range, and how to improve the mixing uniformity of low-dose components, the dispersion and stability of reduced Coenzyme Q10, so that the resulting material is suitable for processing into powders, tablets, or hard capsules. Summary of the Invention

[0003] The purpose of this invention is to address the problems existing in the skin-nourishing and nutrient composition, such as the relatively simple configuration of active ingredients, insufficient uniformity of low-added components in the solid powder system, the high fat solubility of reduced coenzyme Q10 and the difficulty in maintaining its stability during processing and storage, and the difficulty in simultaneously ensuring the dispersion stability and compatibility with solid food processing after the compounding of multiple active raw materials. The invention provides a skin-nourishing and barrier-maintaining composition containing S-estradiol, reduced coenzyme Q10, and ceramides, which has a reasonable configuration of active ingredients, uniform distribution of low-added components, good dispersion and stability of reduced coenzyme Q10, and is suitable for solid food processing.

[0004] To achieve the above objectives, the technical solution adopted by the present invention is: a skin-moisturizing and barrier-maintaining composition containing S-estrol, reduced coenzyme Q10 and ceramide, characterized in that it comprises the following raw materials: 3-10 parts of S-estrol, 30-100 parts of reduced coenzyme Q10, concentrated Pleurotus ostreatus powder, 240-520 parts of lipid complex matrix, 100-280 parts of solid filler, 180-480 parts of dextrin carrier, 2-10 parts of inorganic anti-caking agent and 10-120 parts of flavoring agent;

[0005] The lipid complex matrix comprises a composite particle body, a lipid surface phase, and a protein interface phase. The composite particle body is composed of high-amylose corn starch, β-cyclodextrin, and trehalose, wherein β-cyclodextrin and trehalose are distributed in the starch matrix formed by the high-amylose corn starch and its adjacent regions. The lipid surface phase contains defatted sunflower seed phospholipids and glyceryl monostearate, which are distributed on at least a portion of the surface of the composite particle body and its adjacent regions. The protein interface phase contains sodium caseinate, which is at least partially distributed in the adjacent regions of the composite particle body and the lipid surface phase, and forms an interfacial binding region with both. The lipid surface phase is continuously or discontinuously distributed on the surface of the composite particle body, and all structural regions together constitute the lipid complex matrix.

[0006] Furthermore, the amount of the concentrated Pleurotus ostreatus powder added is calculated based on the mass of ceramide contained therein, so that each serving contains 2-10 servings of ceramide provided by the concentrated Pleurotus ostreatus powder.

[0007] Furthermore, the lipid complex matrix, by weight, is composed of the following raw materials: 40-48 parts of high amylose corn starch, 18-24 parts of β-cyclodextrin, 12-16 parts of sodium caseinate, 14-18 parts of defatted sunflower seed phospholipids, 8-12 parts of glyceryl monostearate, and 6-10 parts of trehalose.

[0008] Furthermore, the preparation method of the lipid complex matrix includes the following steps:

[0009] S1. Add 520-620 parts of deionized water to a pressure-resistant jacketed stirring container, adjust the temperature to 48-52℃, add the high amylose corn starch at 700-900 r / min and stir for 20-30 min; seal the pressure-resistant jacketed stirring container, raise the temperature to 118-122℃ and keep it at that temperature for 20-30 min, then lower the temperature to 58-62℃; add 8-14 parts of a 10% citric acid aqueous solution, adjust the pH of the system to 5.2-5.5, then add pullulanase, the amount of pullulanase added is 20-35 U / g based on the mass of the high amylose corn starch, and treat at 58-62℃ and 300-500 r / min for 120-180 min; after treatment, raise the temperature of the system to 90-95℃ and keep it at that temperature for 10-15 min, then lower the temperature to 68-72℃ to obtain a debranched starch base solution.

[0010] S2. Add 90-120 parts of deionized water to another jacketed stirring vessel and heat to 68-72℃. Add the β-cyclodextrin and trehalose sequentially at 500-700 r / min and continue stirring for 25-35 min to obtain a cyclodextrin sugar solution. Keep the temperature of the debranched starch base solution at 68-72℃ and stir at 700-900 r / min. Add the cyclodextrin sugar solution to the debranched starch base solution at a rate of 2-4 mL / min. After the addition is complete, continue stirring for 40-60 min and then let it stand at 68-72℃ for 20-30 min to obtain a starch-cyclodextrin pre-assembled solution.

[0011] S3. Add the defatted sunflower seed phospholipids and glyceryl monostearate to a third jacketed container, heat to 68-72°C under nitrogen protection, add 35-50 parts of 95% ethanol (volume fraction), and stir at 400-600 r / min for 20-30 min to obtain a lipid dispersion; keep the starch-cyclodextrin pre-assembled solution at 68-72°C, add the lipid dispersion at a rate of 1.0-2.0 mL / min under shear conditions of 8000-10000 r / min, continue shearing for 8-12 min after addition, then switch to 600-800 r / min for stirring and keep warm for 45-60 min; cool the system to 43-47°C, and treat under reduced pressure at -0.085~-0.070 MPa for 25-35 min to obtain a lipid complex solution.

[0012] S4. Add the sodium caseinate to 80-110 parts of deionized water and stir for 25-35 minutes at 43-47℃ and 500-700 r / min to obtain a sodium caseinate solution; add the sodium caseinate solution to the lipid composite solution and stir for 20-30 minutes at 600-800 r / min; add 4-8 parts of a 10% sodium bicarbonate aqueous solution to adjust the pH of the system to 6.5-6.8; add transglutaminase, the amount of transglutaminase added is 15-25 U / g based on the mass of sodium caseinate, and treat for 90-150 minutes at 45-50℃ and 300-500 r / min; after treatment, raise the temperature of the system to 82-86℃ and keep it at that temperature for 10-15 minutes, and then lower it to 60-65℃ to obtain a composite matrix slurry.

[0013] S5. The composite matrix slurry is kept under stirring at 200-300 r / min and cooled from 60-65℃ to 24-28℃ at a cooling rate of 0.5-1.0℃ / min. It is then allowed to stand at 24-28℃ for 60-90 min, and then transferred to 2-6℃ and allowed to stand for 8-12 h. The resulting material is pre-frozen at -45~-38℃ for 6-10 h, and then freeze-dried under a vacuum of 20-50 Pa. The first drying temperature is -25~-15℃ and the time is 10-14 h, and the second drying temperature is 20-25℃ and the time is 4-6 h. After freeze-drying, the material is pulverized and passed through a 100-mesh sieve to obtain the lipid composite matrix.

[0014] Furthermore, the inorganic anti-caking agent is selected from at least one of silicon dioxide and tricalcium phosphate.

[0015] Furthermore, the flavoring agent is selected from at least one of erythritol and xylitol.

[0016] Furthermore, the solid filler is microcrystalline cellulose.

[0017] Furthermore, the dextrin carrier is maltodextrin.

[0018] A skin-moisturizing and barrier-maintaining composition containing S-estradiol, reduced coenzyme Q10 and ceramide, wherein the food form of the composition is selected from powder, tablet and hard capsule.

[0019] A method for preparing a skin-moisturizing and barrier-maintaining composition containing S-estradiol, reduced coenzyme Q10, and ceramides includes the following steps:

[0020] B1. Take 30-40% of the total amount of the maltodextrin and add it to the first dry mixing container along with the microcrystalline cellulose. Mix at 25-35 r / min for 10-15 min. Add the inorganic anti-caking agent and continue mixing for 5-8 min. Pass the resulting mixture through a 40-60 mesh sieve to obtain the first dry powder carrier. Pass the remaining maltodextrin through a 40-60 mesh sieve to obtain the second dry powder carrier.

[0021] B2. Take a portion of the first dry powder carrier and mix it with the S-estrol in equal increments through a stepwise diffusion process. First, mix the S-estrol with the first dry powder carrier at a rate of not less than 1 times its mass and not more than 2 times its mass at 20-30 r / min for 6-10 min. Then, add the first dry powder carrier in increments of 1-2 times the mass of the resulting mixture and perform 2-3 diffusion mixtures, each lasting 6-10 min. After completion, pass the mixture through a 60-80 mesh sieve to obtain the S-estrol premix. Separately, add the lipid complex matrix to a jacketed sealed mixing container. Under nitrogen protection, adjust the material temperature to 47-51℃. Add the reduced coenzyme Q10 in portions at a rate of 100-180 r / min. After all the material has been added, continue mixing for 15-25 min. Then, lower the material temperature to 24-28℃ and pass the mixture through a 40-60 mesh sieve to obtain the reduced coenzyme Q10-complex matrix premix.

[0022] B3. Add the S-estrol premix, reduced coenzyme Q10-complex matrix premix, the remaining first dry powder carrier, and the second dry powder carrier to the second dry mixing container, and mix at 70-120 r / min for 12-18 min; reduce the mixing speed to 30-60 r / min, add the concentrated powder of Pleurotus ostreatus according to the mass conversion of ceramide, and continue mixing for 8-12 min; then add the flavoring agent, and mix at 30-60 r / min for 5-8 min to obtain the composition base; the material temperature is maintained at 20-28℃ during the mixing process in B3.

[0023] B4. According to the predetermined food form, the composition base material is sieved and quantitatively packaged to obtain powder; or the composition base material is directly compressed into tablets to obtain tablets; or the composition base material is quantitatively filled into hard capsule shells to obtain hard capsules.

[0024] Furthermore, when preparing the reduced coenzyme Q10-complex matrix premix in B2, 40-50% of the total mass of the lipid complex matrix is ​​first added to the jacketed sealed mixing container, preheated at 47-51℃ for 8-15 min, and then all of the reduced coenzyme Q10 is uniformly added within 8-15 min; then the remaining lipid complex matrix is ​​divided into two portions and added sequentially, and after each portion is added, it is mixed at 120-180 r / min for 8-12 min; after all the addition is completed, the temperature is reduced to 24-28℃ under continuous nitrogen protection and stirring at 80-120 r / min at a cooling rate of 0.5-1.0℃ / min.

[0025] Furthermore, in B4, when preparing powder, the composition base material is passed through a 30-50 mesh sieve and then quantitatively dispensed using nitrogen filling; when preparing tablets, the composition base material is equilibrated at 20-25℃ for 30-60 minutes and then directly compressed into tablets, with a single-punch compression force of 6-14 kN for the tablet press; when preparing hard capsules, the composition base material is passed through a 30-50 mesh sieve and then filled into gelatin hard capsule shells or hydroxypropyl methylcellulose hard capsule shells, and then sealed and packaged after filling.

[0026] Compared with the prior art, the beneficial effects of the present invention are:

[0027] 1. This invention addresses the problem of localized distribution differences that easily occur when low-dosage active ingredients are directly mixed with large proportions of excipients in existing solid nutritional compositions. In the preparation process, S-estrol is premixed using a stepwise equal-volume diffusion method before being mixed with the remaining powders in stages. This treatment allows low-dose S-estrol to diffuse first within a portion of the carrier before entering the overall powder system. Compared to direct one-time mixing, this method is more effective in controlling content differences at different sampling locations. The detection trends at different layers in performance testing correspond to this preparation design, ensuring a relatively consistent distribution of active ingredients during subsequent packaging, tableting, or capsule filling.

[0028] 2. This invention addresses the problems of reduced coenzyme Q10's high lipid solubility, limited dispersion in ordinary dry powder carriers, and potential changes in its reduced state during storage. It introduces a lipid complex matrix composed of a starch matrix, β-cyclodextrin, trehalose, a lipid surface phase, and a sodium caseinate interface region. Reduced coenzyme Q10 is added to this matrix in stages under nitrogen protection and controlled temperature conditions, maintaining greater contact with the regions containing defatted sunflower seed phospholipids and glyceryl monostearate, while the starch and protein components provide a solid support. Compared to systems using conventional alternative raw materials or without a lipid complex matrix, its dispersion state and the tendency to maintain its reduced state after storage better align with the design objectives of this invention.

[0029] 3. This invention considers the processing requirements of solid foods while loading active ingredients. It uses debranched high-amylose corn starch, β-cyclodextrin, and trehalose to form the main body of composite particles. A lipid phase containing phospholipids and glyceryl monostearate, and a protein interface region containing sodium caseinate are formed on the particle surface and adjacent areas. The powder matrix is ​​then obtained through cooling, settling, freeze-drying, pulverizing, and sieving. Compared to simply using ordinary starch, maltodextrin, or conventional proteins to replace some structural components, this structure has different effects on the contact, packing, and flow state between powder particles. The trends in flowability, bulk density, and tap density tests indicate that this matrix not only serves as a carrier of active ingredients but also participates in regulating the final powder processing state.

[0030] 4. This invention incorporates S-equorol, reduced coenzyme Q10, and ceramide-derived components from concentrated Pleurotus ostreatus powder into a single solid composition. Premixing and addition methods are tailored to address the differences in dosage, hydrophilicity / hydrophobicity, and processing stability of the three raw materials. S-equorol's distribution in the powder is primarily controlled through stepwise diffusion; reduced coenzyme Q10's carrying capacity in the system is improved through a lipid complex matrix; and the ceramide-derived raw material is added after adjusting for the effective ingredient content. Compared to formulations retaining only one or two core active ingredients, the complete composition exhibits different trends in in vitro barrier restoration evaluations, indicating that the three raw materials participate in the overall effect of the composition from different nutritional and barrier-related aspects. Attached Figure Description

[0031] Figure 1 The image shows the SEM morphology of the lipid complex matrix prepared in Example 1 of this invention.

[0032] Figure 2 The infrared spectrum of the lipid complex matrix prepared in Example 1 of this invention is shown. Detailed Implementation

[0033] The technical solution of the present invention will now be clearly and completely described with reference to the accompanying drawings. Obviously, the described embodiments are merely some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.

[0034] Preparation Example 1

[0035] Preparation of lipid complex matrix:

[0036] 1. Raw material composition:

[0037] By weight, it includes the following raw materials:

[0038] High amylose corn starch: 44 parts; β-cyclodextrin: 21 parts; sodium caseinate: 14 parts; defatted sunflower seed phospholipids: 16 parts; glyceryl monostearate: 10 parts; trehalose: 8 parts.

[0039] The high amylose corn starch was purchased from Ingredion Incorporated, and its product name is HYLON. ® VII-03451B00.

[0040] The β-cyclodextrin was purchased from Shanghai Maclean Biochemical Technology Co., Ltd., with product number C6289.

[0041] The deoiled sunflower seed phospholipids were purchased from Wuqi Biotechnology Co., Ltd., and the model number is SUNCITHINP96.

[0042] The glyceryl monostearate was purchased from Shanghai McLean Biochemical Technology Co., Ltd., with product number G799115.

[0043] 2. Preparation method:

[0044] S1. Add 570 parts of deionized water to a pressure-resistant jacketed stirring vessel, adjust the water temperature to 50℃, and uniformly add 44 parts of high amylose corn starch over 5 minutes at 800 rpm. After the addition is complete, continue stirring at 50℃ and 800 rpm for 25 minutes. Then, seal the pressure-resistant jacketed stirring vessel and heat to 120℃ at a rate of 2℃ / min, adjusting the stirring speed to 400 rpm during the heating process, and maintain the temperature at 120℃ for 25 minutes. Use steam to maintain the liquid phase without introducing additional pressurized gas. After the holding period, cool to 60℃ at a rate of 2℃ / min. Add a 10% (w / w) citric acid aqueous solution to the system at 60℃ and 400 rpm to adjust the pH to 5.35. Then, add 0.55 mL of pullulanase and treat at 60℃ and 400 rpm for 150 minutes. After the treatment, the system was heated to 92°C at a heating rate of 2°C / min, and kept at 92°C for 12 min to inactivate the enzyme. Then, it was cooled to 70°C at a cooling rate of 2°C / min to obtain the debranched starch base solution.

[0045] The pullulanase used is Sunson Enzymes' Pullulanase UltraP2, with a nominal enzyme activity of 2000 U / mL and an activity temperature range of 40-65℃.

[0046] S2. Add 105 parts of deionized water to another jacketed stirring vessel, adjust the temperature to 70℃, add the 21 parts of β-cyclodextrin within 3 minutes at 600 r / min, and then add the 8 parts of trehalose within 2 minutes. After the addition is complete, continue stirring at 70℃ and 600 r / min for 30 minutes to obtain a cyclodextrin sugar solution. Keep the debranched starch base solution obtained in S1 at 70℃ and stir at 800 r / min. Use a metering pump to add all of the cyclodextrin sugar solution to the debranched starch base solution at a constant volume flow rate of 3.0 mL / min. After the addition is complete, continue stirring at 70℃ and 800 r / min for 50 minutes, then stop stirring and let it stand at 70℃ for 25 minutes to obtain a starch-cyclodextrin pre-assembled solution.

[0047] S3. Add 16 parts of defatted sunflower seed phospholipids and 10 parts of glyceryl monostearate to a third jacketed container. Replace the air in the container with nitrogen gas of at least 99.99% purity, and maintain nitrogen protection throughout the subsequent lipid dispersion stage. Raise the material temperature to 70°C, and add 42 parts of 95% ethanol (volume fraction) within 5 minutes while stirring at 500 rpm. After addition, continue stirring at 70°C, 500 rpm, and nitrogen protection for 25 minutes to form a uniform lipid dispersion. Maintain the starch-cyclodextrin pre-assembled solution obtained in S2 at 70°C, adjust the shear speed to 9000 rpm, and add all of the lipid dispersion using a metering pump at a constant volumetric flow rate of 1.5 mL / min. After addition, continue shearing at 70°C and 9000 rpm for 10 minutes; then reduce the speed to 700 rpm, continue stirring at 70°C, and maintain the temperature for 52 minutes. After the heat preservation was completed, the nitrogen gas supply was stopped, and the system was cooled to 45℃ at a cooling rate of 1.0℃ / min. Then, it was subjected to reduced pressure treatment at 45℃ and -0.078MPa for 30 min to obtain the lipid complex solution.

[0048] S4. Add 95 parts of deionized water to the fourth jacketed stirring vessel, adjust the temperature to 45℃, and add 14 parts of sodium caseinate over 5 minutes at 600 rpm. After the addition is complete, continue stirring at 45℃ and 600 rpm for 30 minutes to obtain a sodium caseinate solution. Add the obtained sodium caseinate solution to the lipid complex solution obtained in S3 over 5 minutes, maintaining the system at 45℃ and stirring at 700 rpm during the addition process. After the addition is complete, continue stirring at 45℃ and 700 rpm for 25 minutes. Add a 10% sodium bicarbonate aqueous solution to the system and adjust the pH to 6.65. Then add 0.280 parts of transglutaminase; adjust the system temperature to 48℃ and treat at 400 rpm for 120 minutes. After the treatment, the system was heated to 84℃ at a heating rate of 2℃ / min and held at that temperature for 12 min; then the system was cooled to 62℃ at a cooling rate of 1.5℃ / min to obtain the composite matrix slurry.

[0049] The transglutaminase used is TG-H from Jiangsu Yiming Biotechnology Co., Ltd., with a specification of 1000U / g.

[0050] S5. The composite matrix slurry obtained in S4 was kept under stirring at 250 r / min and cooled from 62℃ to 26℃ at a cooling rate of 0.75℃ / min for 48 min. After reaching 26℃, stirring was stopped, and the mixture was allowed to stand at 26℃ for 75 min. The material was then transferred to 4℃ and allowed to stand for 10 h. After standing, the resulting material was spread in a freeze-drying tray with a layer thickness of 8 mm and pre-frozen at -40℃ for 8 h. After pre-freezing, the mixture was transferred to the freeze-drying program and dried once under a vacuum of 30 Pa at a temperature of -20℃ for 12 h. After the first drying, the material temperature was raised to 23℃ at a heating rate of 0.5℃ / min while maintaining a vacuum of 30 Pa, and then dried a second time at 23℃ for 5 h. After the second drying, the vacuum was released, and the dried material was pulverized, with the material temperature controlled not to exceed 30℃ during pulverization. The pulverized material was then passed through a 100-mesh sieve, and the material passing through the 100-mesh sieve was collected to obtain the lipid composite matrix.

[0051] like Figure 1As shown in the figure, the sample exhibits an irregular blocky, flaky, and broken granular structure, with particle sizes mainly in the tens of micrometers range, consistent with the particle size characteristics of powders obtained after freeze-drying, pulverizing, and passing through a 100-mesh sieve. The surfaces of each particle are noticeably rough, with numerous wrinkles, depressions, and interconnected micrometer-sized pores. A relatively continuous honeycomb or network-like porous framework can be observed, unlike the more regular and dense particle morphology of high-amylose corn starch or β-cyclodextrin when they exist alone. This indicates that the system has formed a new continuous matrix structure after debranching, pre-assembly, and subsequent composite treatment. Rounded protrusions and granular attachment structures are also visible on some framework surfaces and pore walls, but these are relatively continuous with the main body interface. No obvious large-scale plate-like crystals, independent lipid clusters, or severe phase separation were observed. This is consistent with the structural characteristics of the heterogeneous composite matrix composed of the starch-cyclodextrin main body, phospholipid / glyceryl monostearate lipid regions, and sodium caseinate component. Meanwhile, the open pores and skeleton walls remaining after the removal of the aqueous phase during the freeze-drying process further reflect that a three-dimensional network with a certain degree of continuity has been formed in the slurry stage.

[0052] like Figure 2 As shown, at approximately 3310cm -1 A broad and distinct absorption band appears at approximately 2940 cm⁻¹, mainly corresponding to the OH stretching vibrations of the abundant hydroxyl groups in starch, β-cyclodextrin, and trehalose, and somewhat overlapping with the NH stretching vibrations in sodium caseinate, indicating that the system has a polysaccharide-protein complex structure rich in hydroxyl and amide groups; at approximately 2940 cm⁻¹... -1 and 2880cm -1 An aliphatic CH stretching vibration absorption peak appears at approximately 1727 cm⁻¹, corresponding to the long-chain hydrocarbon structure in defatted sunflower seed phospholipids and glyceryl monostearate. -1 Characteristic absorption of the C=O stretching vibration of the ester group can be observed at approximately 1649 cm⁻¹, indicating that the ester bond structure of phospholipids and glyceryl monostearate is retained in the composite matrix; -1 and 1530cm -1 The presence of distinct amide I and amide II bands at the locations indicated that the protein backbone of sodium caseinate was consistent with that of the obtained complex system, suggesting the presence of protein components. (Approximately 1462 cm⁻¹) -1 The absorption at this point can be attributed to the -CH2- bending vibration; approximately 1230 cm⁻¹ -1 The nearby absorption coincides with the vibrational correlation of phosphate groups in phospholipids. This is especially true at approximately 1081 cm⁻¹. -1 and 1013cm -1A strong absorption peak is formed at the point, mainly corresponding to the COC glycosidic bond and CO stretching vibration in starch, β-cyclodextrin, and trehalose, and partially overlaps with the POC-related vibration of phospholipids. The characteristic absorption peaks of the above polysaccharide, protein, and lipid components appear simultaneously in the same spectrum, and no obvious abnormal absorption peaks of new functional groups are found, indicating that each structural unit is preserved during the preparation process and coexists in the resulting matrix.

[0053] Comparative Preparation Example 1

[0054] The lipid complex matrix was prepared by referring to the preparation method in Preparation Example 1, except that the high amylose corn starch was replaced with ordinary corn starch, and everything else remained the same as in Preparation Example 1.

[0055] Comparative Preparation Example 2

[0056] The lipid complex matrix was prepared according to the preparation method in Preparation Example 1, except that the β-cyclodextrin was replaced with maltodextrin by mass, and everything else remained the same as in Preparation Example 1.

[0057] Comparative preparation example 3

[0058] The lipid complex matrix was prepared by referring to the preparation method in Preparation Example 1, except that the sodium caseinate and other components were replaced with soy protein isolate, while the rest remained the same as in Preparation Example 1.

[0059] The soy protein isolate was purchased from Shandong Jiahe Biotechnology Co., Ltd., and its model number is ISOPRO910.

[0060] Comparative preparation example 4

[0061] The lipid complex matrix was prepared by referring to the preparation method in Preparation Example 1, except that the amount of deoiled sunflower seed phospholipid was replaced with soybean lecithin, and everything else remained the same as in Preparation Example 1.

[0062] The soybean lecithin mentioned was purchased from Hebei Desong Biotechnology Co., Ltd., and its model number is PC50.

[0063] Comparative preparation example 5

[0064] The lipid complex matrix was prepared by referring to the preparation method in Preparation Example 1, except that the mass of glyceryl monostearate was replaced with sucrose fatty acid ester, and everything else remained the same as in Preparation Example 1.

[0065] Example 1

[0066] Preparation of a skin-moisturizing and barrier-maintaining composition containing S-estradiol, reduced coenzyme Q10, and ceramides:

[0067] 1. Raw material composition:

[0068] By weight, it includes the following raw materials:

[0069] S-Estrol: 5 parts.

[0070] Reduced Coenzyme Q10: 50 servings.

[0071] Golden Top Pleurotus ostreatus Concentrate Powder: 133.33 parts, calculated as 4 parts based on a ceramide content of 3%.

[0072] Lipid complex matrix: 360 portions of the lipid complex matrix obtained in Example 1.

[0073] Solid filler: microcrystalline cellulose, 190 parts.

[0074] Dextrin carrier: maltodextrin, 320 parts.

[0075] Inorganic anti-caking agent: silicon dioxide, 6 parts.

[0076] Flavoring agent: erythritol, 60 parts.

[0077] The concentrated powder of Pleurotus ostreatus was purchased from Kangtian Biochemical Technology Co., Ltd., and its model number is R151-14-03.

[0078] The microcrystalline cellulose was purchased from Anhui Shanhe Pharmaceutical Excipients Co., Ltd., and the model number is SH-102.

[0079] The silica was purchased from Anhui Shanhe Pharmaceutical Excipients Co., Ltd., and the model number is SH-CD1.

[0080] 2. Preparation method:

[0081] B1. Take 35% of the total 320 parts of maltodextrin, i.e., 112 parts of maltodextrin, and add them sequentially to the first dry mixing container along with the 190 parts of microcrystalline cellulose. The solid raw material feeding process should be completed within 5 minutes. Mix for 12 minutes at 25°C and 30 rpm. Then add the 6 parts of silica, and complete the feeding process within 2 minutes. Continue mixing for 6 minutes at 25°C and 30 rpm. Pass the resulting mixture through a 50-mesh sieve to obtain 308 parts of the first dry powder carrier. Pass the remaining 208 parts of maltodextrin separately through a 50-mesh sieve to obtain the second dry powder carrier.

[0082] B2. Take 5 parts of S-estrol and 5 parts of the first dry powder carrier and add them to a dry mixing container. Mix at 25°C and 25 rpm for 8 min. Then add 10 parts of the first dry powder carrier within 2 min and continue mixing at 25 rpm for 8 min. Then add 20 parts of the first dry powder carrier within 3 min and continue mixing at 25 rpm for 8 min. Pass the resulting material through a 70-mesh sieve to obtain 40 parts of S-estrol premix. Take 45% of the total 360 parts of the lipid complex matrix, i.e., 162 parts of the lipid complex matrix, and add it to a jacketed sealed mixing container. Replace the air in the container with nitrogen gas with a purity of not less than 99.99%, and maintain nitrogen protection continuously during the subsequent premixing of reduced coenzyme Q10. Adjust the material temperature to 49°C and preheat for 10 min. At 49°C and 150 rpm, add all 50 parts of reduced coenzyme Q10 evenly within 10 min, with an average solid feeding rate of 5 parts / min. The remaining 198 lipid complex matrices were divided into two equal portions of 99 parts each. The first portion was added uniformly over 3 minutes, and after addition, it was mixed for 10 minutes at 49°C and 150 rpm. The second portion was added in the same manner over 3 minutes, and after addition, it was mixed for another 10 minutes at 49°C and 150 rpm. After all materials were added, mixing continued for 20 minutes at 49°C, 150 rpm, and under continuous nitrogen protection. Subsequently, while maintaining nitrogen protection, the mixing speed was reduced to 100 rpm, and the material was cooled from 49°C to 26°C at a cooling rate of 0.75°C / min. The resulting material was then passed through a 50-mesh sieve to obtain 410 parts of reduced coenzyme Q10-complex matrix premix.

[0083] B3. The 40 parts of S-estrol premix, 410 parts of reduced coenzyme Q10-complex matrix premix, the remaining 273 parts of the first dry powder carrier, and 208 parts of the second dry powder carrier obtained in B2 were sequentially added to the second dry mixing container. Solid addition was completed within 8 minutes, with the material temperature controlled at 24°C, and mixing was performed at 90 r / min for 15 minutes. Then, the mixing speed was reduced to 45 r / min, and the 133.33 parts of *Pleurotus ostreatus* concentrate powder were added uniformly over 10 minutes, with an average solid addition rate of 13.333 parts / min. After addition, mixing continued at 24°C and 45 r / min for 10 minutes. Next, the 60 parts of erythritol were added uniformly over 3 minutes, with an average solid addition rate of 20 parts / min. After addition, mixing continued at 24°C and 45 r / min for 6 minutes to obtain the composition base.

[0084] B4. Pass the composition base material obtained in B3 through a 40-mesh sieve and collect the material passing through the 40-mesh sieve; quantitatively dispense the material under nitrogen protection with a purity of not less than 99.99%, and seal the package immediately after nitrogen filling to obtain the skin-nourishing and barrier-maintaining composition powder containing S-estrol, reduced coenzyme Q10 and ceramide.

[0085] Example 2

[0086] A skin-moisturizing and barrier-maintaining composition containing S-equorol, reduced coenzyme Q10, and ceramide was prepared by referring to the preparation method of Example 1, with the following adjustments to the amounts of each raw material: 3 parts S-equorol, 30 parts reduced coenzyme Q10, 66.67 parts concentrated Pleurotus ostreatus powder (with ceramide counted as 2 parts), 240 parts lipid complex matrix, 100 parts microcrystalline cellulose, 180 parts maltodextrin, 2 parts silica, and 10 parts erythritol. The amounts of raw materials used in each step, determined by total amount, mass percentage, or mass multiple, were calculated based on the corresponding amounts of raw materials in this example. The rest remained the same as in Example 1.

[0087] Example 3

[0088] A skin-moisturizing and barrier-maintaining composition containing S-estrol, reduced coenzyme Q10, and ceramide was prepared according to the preparation method of Example 1, with the following adjustments to the amounts of each raw material: 10 parts S-estrol, 100 parts reduced coenzyme Q10, 333.33 parts concentrated Pleurotus ostreatus powder (with ceramide counted as 10 parts), 520 parts lipid complex matrix, 280 parts microcrystalline cellulose, 480 parts maltodextrin, 10 parts silica, and 120 parts erythritol. The amounts of raw materials used in each step, determined by total amount, percentage, or multiple of mass, were calculated based on the corresponding amounts of raw materials in this example. The rest remained the same as in Example 1.

[0089] Example 4

[0090] The preparation of a skin-moisturizing and barrier-maintaining composition containing S-estrol, reduced coenzyme Q10 and ceramide is carried out by referring to the preparation method of Example 1, except that the silica is replaced by tricalcium phosphate, and the rest is the same as in Example 1.

[0091] Example 5

[0092] The preparation of a skin-moisturizing and barrier-maintaining composition containing S-estradiol, reduced coenzyme Q10 and ceramide is carried out by referring to the preparation method of Example 1, except that the erythritol and other components are replaced with xylitol, and the rest is the same as in Example 1.

[0093] Comparative Examples 1-5

[0094] The preparation of a skin-moisturizing and barrier-maintaining composition containing S-estrol, reduced coenzyme Q10 and ceramide was carried out by referring to the preparation method of Example 1, except that the lipid complex matrix was replaced sequentially with the lipid complex matrix in Comparative Preparation Examples 1-5, and the rest remained unchanged from Example 1.

[0095] Comparative Example 6

[0096] The preparation of a skin-moisturizing and barrier-maintaining composition containing S-estrol, reduced coenzyme Q10 and ceramide is carried out according to the preparation method of Example 1, except that the lipid complex carrier is not added, and the rest remains unchanged from Example 1.

[0097] Comparative Example 7

[0098] The preparation of a skin-moisturizing and barrier-maintaining composition containing S-estrol was carried out according to the preparation method of Example 1, except that only 5 parts of S-estrol were retained, and reduced coenzyme Q10 and Pleurotus ostreatus concentrate were not added. The remaining raw materials and their amounts were the same as in Example 1. The feeding steps corresponding to the reduced coenzyme Q10 and Pleurotus ostreatus concentrate were omitted in the preparation process, and the rest was the same as in Example 1.

[0099] Comparative Example 8

[0100] The preparation of a skin-moisturizing and barrier-maintaining composition containing reduced coenzyme Q10 is carried out according to the preparation method of Example 1, except that only 50 parts of reduced coenzyme Q10 are retained, and S-estrol and Pleurotus ostreatus concentrate are not added. The remaining raw materials and their amounts are the same as in Example 1. The feeding steps corresponding to the S-estrol and Pleurotus ostreatus concentrate are omitted in the preparation process, and the rest is the same as in Example 1.

[0101] Comparative Example 9

[0102] The preparation of a skin-moisturizing and barrier-maintaining composition containing ceramides was carried out according to the preparation method of Example 1, except that 133.33 parts of the concentrated powder of Pleurotus ostreatus was retained, which was converted into 4 parts of ceramide based on the mass fraction of 3%. S-estrol and reduced coenzyme Q10 were not added, and the remaining raw materials and their amounts were the same as in Example 1. The feeding steps corresponding to S-estrol and reduced coenzyme Q10 were omitted in the preparation process, and the rest was the same as in Example 1.

[0103] Comparative Example 10

[0104] The preparation of a skin-moisturizing and barrier-maintaining composition containing S-estrol, reduced coenzyme Q10 and ceramide is carried out according to the preparation method of Example 1, retaining 5 parts of S-estrol and 50 parts of reduced coenzyme Q10, without adding Pleurotus ostreatus concentrate, and the remaining raw materials and their amounts are the same as in Example 1; the step of adding Pleurotus ostreatus concentrate is omitted in the preparation process, and the rest is the same as in Example 1.

[0105] Comparative Example 11

[0106] The preparation of a skin-moisturizing and barrier-maintaining composition containing S-estrol, reduced coenzyme Q10, and ceramide is carried out according to the preparation method of Example 1, retaining 5 parts of S-estrol and 133.33 parts of Pleurotus ostreatus extract concentrate, wherein the Pleurotus ostreatus extract concentrate is calculated as 4 parts of ceramide, and no reduced coenzyme Q10 is added. The remaining raw materials and their amounts are the same as in Example 1. The step of adding the reduced coenzyme Q10 is omitted in the preparation process, and the rest is the same as in Example 1.

[0107] Comparative Example 12

[0108] The preparation of a skin-moisturizing and barrier-maintaining composition containing S-estrol, reduced coenzyme Q10, and ceramide is carried out according to the preparation method of Example 1, retaining 50 parts of reduced coenzyme Q10 and 133.33 parts of Pleurotus ostreatus concentrate powder, wherein the Pleurotus ostreatus concentrate powder is calculated as 4 parts of ceramide, and S-estrol is not added. The remaining raw materials and their amounts are the same as in Example 1. The step of adding S-estrol is omitted in the preparation process, and the rest is the same as in Example 1.

[0109] Performance testing:

[0110] 1. S-Estrol Mixing Homogeneity Test: After mixing in each example and Comparative Example B3, 2.00 g of powder was taken from each fixed position in the upper, middle, and lower layers of the mixing container. 80% methanol was added to bring the volume to 50 mL, and the mixture was sonicated for 30 min, centrifuged at 12000 r / min for 10 min, and filtered through a 0.22 μm filter membrane. A C18 column (250 mm × 4.6 mm, 5 μm) was used for gradient elution with acetonitrile-0.1% formic acid aqueous solution: acetonitrile 20% in 0-2 min, linearly increasing to 45% in 2-12 min, and recovering to 20% in 12-15 min; flow rate 1.0 mL / min, column temperature 30℃, detection at 280 nm. The content at each position was calculated using the external standard method and expressed in mg / part. The data are shown in Table 1.

[0111] 2. Storage stability test of reduced coenzyme Q10: The final nitrogen-sealed sample was placed at 40℃ and 75% relative humidity for 30 days. 1.00 g samples were taken on days 0 and 30, and 25 mL of pre-deoxygenated isopropanol-n-hexane (20:80, v / v) was added under nitrogen protection. Extraction was performed by shaking for 10 min, followed by centrifugation at 6000×g for 5 min. Elution was performed using a C18 column (250 mm × 4.6 mm, 5 μm) with isocratic elution in methanol-ethanol (65:35, v / v) at a flow rate of 1.0 mL / min, a column temperature of 35℃, and detection at 275 nm. Quantification was performed using reduced coenzyme Q10 standard external standard. The content retention rate was calculated as 30-day content / 0-day content × 100%. Data are shown in Table 1.

[0112] 3. Powder Flowability Index Test: The final powders obtained in the examples and comparative examples were used as test samples, and the test was conducted strictly in accordance with the sample preparation, testing procedures, and result calculation methods specified in GB / T31057.3-2018. All samples were prepared under the same conditions and environmental conditions, without altering the key steps specified in the standard, and the flowability index was recorded. The data are shown in Table 1.

[0113] 4. Loose Packing Density and Tapped Density Tests: The final powder was used as the test sample. The loose packaging density was strictly determined according to GB / T31057.1-2014; the tapped density was strictly determined according to GB / T31057.2-2018. The sample was not compacted before testing. The loose packaging density and tapped density were recorded separately, in g / mL. The data are shown in Table 1.

[0114] 5. In vitro skin barrier recovery test: A commercially available reconstructed human epidermal model was used. Each sample was added to 100 mL of pH 2.0 simulated gastric juice, and pepsin was added to a concentration of 2000 U / mL. Digestion was performed at 37°C for 60 min. The pH was adjusted to 7.0, and trypsin (100 U / mL) and bile salts (10 mmol / L) were added. Digestion was continued at 37°C for 120 min, followed by centrifugation at 10000×g for 10 min. The supernatant was then diluted 10-fold with culture medium. The model was treated with 0.05% sodium dodecyl sulfate for 10 min, washed, and the digested solution was added to the basal side for 24 h of incubation. Transepithelial electrical resistance was recorded before, after, and after incubation. The barrier recovery rate was calculated as (resistance after incubation - resistance after injury) / (resistance before injury - resistance after injury) × 100%. The data are shown in Table 1.

[0115] Table 1. Performance test results of each embodiment and comparative example

[0116]

[0117] Note: " / " in the table indicates that the corresponding sample does not contain the active ingredient to be tested, and therefore this content test is not performed.

[0118] The test trends show that the examples maintained similar levels in terms of spatial distribution of low-dose S-estrol, storage state of reduced coenzyme Q10, and powder flow and stacking behavior. This indicates that the stepwise equal-volume diffusion mixing, nitrogen-protected premixing, and lipid complex matrix structure design can address different issues in low-dosage component mixing, lipid-soluble component dispersion, and solid powder processing, respectively. In the lipid complex matrix, debranched high-amylose corn starch forms the granule matrix, β-cyclodextrin and trehalose are located in the starch matrix and adjacent regions, defatted sunflower seed phospholipids and glyceryl monostearate constitute the lipid surface phase, and sodium caseinate is located in the interfacial region between the matrix and the lipid phase. This structure allows reduced coenzyme Q10 to have a lipid phase contact region during the premixing stage and maintains the corresponding interfacial continuity and stacking characteristics of the dried powder. In the comparative preparation examples, after replacing each of the high-amylose corn starch, β-cyclodextrin, sodium caseinate, sunflower seed phospholipids, or glyceryl monostearate, the retention of reduced coenzyme Q10, powder flowability, and in vitro barrier recovery all showed a decreasing trend. The decrease was further amplified after removing the lipid complex matrix, indicating that the aforementioned structural regions were not solely borne by any conventional substitute. In the examples, replacing silica with tricalcium phosphate and erythritol with xylitol resulted in minimal changes to the core indicators, demonstrating that replacing the anti-caking agents and flavoring agents listed in the claims does not alter the main technical route. The proportions retaining only one or two core active ingredients showed lower in vitro barrier recovery indicators than the complete composition, indicating that S-estradiol, reduced coenzyme Q10, and ceramide-derived raw materials each perform different nutritional and barrier-related functions, and the simultaneous presence of all three better aligns with the combined design of this invention for skin elasticity and barrier maintenance.

[0119] Although embodiments of the invention have been shown and described, it will be understood by those skilled in the art that various changes, modifications, substitutions and alterations can be made to these embodiments without departing from the principles and spirit of the invention, the scope of which is defined by the appended claims and their equivalents.

Claims

1. A moisturizing, soothing, skin care and barrier maintenance composition comprising S-equol, reduced coenzyme Q10 and ceramide, characterized in that, Including the following raw materials: S-Estrol 3-10 parts, Reduced Coenzyme Q10 30-100 parts, Golden Top Pleurotus ostreatus concentrated powder, Lipid complex matrix 240-520 parts, Solid filler 100-280 parts, Dextrin carrier 180-480 parts, Inorganic anti-caking agent 2-10 parts, and Flavoring agent 10-120 parts. The amount of the concentrated Pleurotus ostreatus powder added is calculated based on the mass of ceramides contained therein, so that each part contains 2-10 parts of ceramides provided by the concentrated Pleurotus ostreatus powder. The lipid complex matrix, by weight, is composed of the following raw materials: 40-48 parts of high amylose corn starch, 18-24 parts of β-cyclodextrin, 12-16 parts of sodium caseinate, 14-18 parts of defatted sunflower seed phospholipids, 8-12 parts of glyceryl monostearate, and 6-10 parts of trehalose.

2. The skin care composition comprising S-equol, reduced coenzyme Q10 and ceramide according to claim 1, wherein, The preparation method of the lipid complex matrix includes the following steps: S1. Add 520-620 parts of deionized water to a pressure-resistant jacketed stirring container, adjust the temperature to 48-52℃, add the high amylose corn starch at 700-900 r / min and stir for 20-30 min; seal the pressure-resistant jacketed stirring container, raise the temperature to 118-122℃ and keep it at that temperature for 20-30 min, then lower the temperature to 58-62℃; add 8-14 parts of a 10% citric acid aqueous solution, adjust the pH of the system to 5.2-5.5, then add pullulanase, the amount of pullulanase added is 20-35 U / g based on the mass of the high amylose corn starch, and treat at 58-62℃ and 300-500 r / min for 120-180 min; after treatment, raise the temperature of the system to 90-95℃ and keep it at that temperature for 10-15 min, then lower the temperature to 68-72℃ to obtain a debranched starch base solution; S2. Add 90-120 parts of deionized water to another jacketed stirring vessel and heat to 68-72℃. Add the β-cyclodextrin and trehalose sequentially at 500-700 r / min and continue stirring for 25-35 min to obtain a cyclodextrin sugar solution. Keep the temperature of the debranched starch base solution at 68-72℃ and stir at 700-900 r / min. Add the cyclodextrin sugar solution to the debranched starch base solution at a rate of 2-4 mL / min. After the addition is complete, continue stirring for 40-60 min and then let it stand at 68-72℃ for 20-30 min to obtain a starch-cyclodextrin pre-assembled solution. S3. Add the defatted sunflower seed phospholipids and glyceryl monostearate to a third jacketed container, heat to 68-72°C under nitrogen protection, add 35-50 parts of 95% ethanol (volume fraction), and stir at 400-600 r / min for 20-30 min to obtain a lipid dispersion; keep the starch-cyclodextrin pre-assembled solution at 68-72°C, add the lipid dispersion at a rate of 1.0-2.0 mL / min under shear conditions of 8000-10000 r / min, continue shearing for 8-12 min, then switch to 600-800 r / min and keep warm for 45-60 min; cool the system to 43-47°C, and treat under reduced pressure at -0.085~-0.070 MPa for 25-35 min to obtain a lipid complex solution; S4. Add the sodium caseinate to 80-110 parts of deionized water and stir for 25-35 minutes at 43-47℃ and 500-700 r / min to obtain a sodium caseinate solution; add the sodium caseinate solution to the lipid composite solution and stir for 20-30 minutes at 600-800 r / min; add 4-8 parts of a 10% sodium bicarbonate aqueous solution to adjust the pH of the system to 6.5-6.8; add transglutaminase, the amount of transglutaminase added is 15-25 U / g based on the mass of sodium caseinate, and treat for 90-150 minutes at 45-50℃ and 300-500 r / min; after treatment, raise the temperature of the system to 82-86℃ and keep it at that temperature for 10-15 minutes, then lower the temperature to 60-65℃ to obtain a composite matrix slurry; S5. The composite matrix slurry is kept under stirring at 200-300 r / min and cooled from 60-65℃ to 24-28℃ at a cooling rate of 0.5-1.0℃ / min. It is then allowed to stand at 24-28℃ for 60-90 min, and then transferred to 2-6℃ and allowed to stand for 8-12 h. The resulting material is pre-frozen at -45~-38℃ for 6-10 h, and then freeze-dried under a vacuum of 20-50 Pa. The first drying temperature is -25~-15℃ and the time is 10-14 h, and the second drying temperature is 20-25℃ and the time is 4-6 h. After freeze-drying, the material is pulverized and passed through a 100-mesh sieve to obtain the lipid composite matrix.

3. The S-equol, coenzyme Q10 and ceramide-containing composition for skin moisturization, skin barrier maintenance and skin barrier repair according to claim 1, wherein The inorganic anti-caking agent is selected from at least one of silicon dioxide and tricalcium phosphate.

4. The S-equol, coenzyme Q10 and ceramide-containing composition for skin moisturization, skin barrier maintenance and skin barrier repair according to claim 1, wherein, The flavoring agent is selected from at least one of erythritol and xylitol.

5. The skin-moisturizing and barrier-maintaining composition containing S-estradiol, reduced coenzyme Q10, and ceramide according to claim 1, characterized in that, The solid filler is microcrystalline cellulose.

6. The S-equol, coenzyme Q10 and ceramide-containing composition for skin moisturization, skin barrier maintenance and skin barrier repair according to claim 1, wherein The dextrin carrier is maltodextrin.

7. A skin care and barrier maintenance composition comprising S-equol, reduced coenzyme Q10 and ceramide according to any one of claims 1 to 6, characterized in that, The food form of the composition is selected from one of powder, tablet and hard capsule.

8. A method for preparing a skin-moisturizing and barrier-maintaining composition containing S-estrol, reduced coenzyme Q10, and ceramide as described in any one of claims 1-7, characterized in that, Includes the following steps: B1. Take 30-40% of the total amount of the maltodextrin and add it to the first dry mixing container along with the microcrystalline cellulose. Mix at 25-35 r / min for 10-15 min. Add the inorganic anti-caking agent and continue mixing for 5-8 min. Pass the resulting mixture through a 40-60 mesh sieve to obtain the first dry powder carrier. Pass the remaining maltodextrin through a 40-60 mesh sieve to obtain the second dry powder carrier. B2. Take a portion of the first dry powder carrier and mix it with the S-estrol in equal amounts through stepwise diffusion. First, mix the S-estrol with the first dry powder carrier at a rate of not less than 1 times its mass and not more than 2 times its mass at 20-30 r / min for 6-10 min. Then, add the first dry powder carrier in a single addition amount of 1-2 times the mass of the resulting mixture and perform 2-3 diffusion mixing cycles, each lasting 6-10 min. After completion, pass the mixture through a 60-80 mesh sieve to obtain the S-estrol premix. Separately, add the lipid complex matrix to a jacketed sealed mixing container. Under nitrogen protection, adjust the material temperature to 47-51℃. Add the reduced coenzyme Q10 in portions at a rate of 100-180 r / min. After all the material has been added, continue mixing for 15-25 min. Then, lower the material temperature to 24-28℃ and pass the mixture through a 40-60 mesh sieve to obtain the reduced coenzyme Q10-complex matrix premix. B3. Add the S-estrol premix, reduced coenzyme Q10-complex matrix premix, the remaining first dry powder carrier, and the second dry powder carrier to the second dry mixing container, and mix at 70-120 r / min for 12-18 min; reduce the mixing speed to 30-60 r / min, add the concentrated powder of Pleurotus ostreatus according to the mass conversion of ceramide, and continue mixing for 8-12 min; then add the flavoring agent, and mix at 30-60 r / min for 5-8 min to obtain the composition base; the material temperature is maintained at 20-28℃ during the mixing process in B3; B4. According to the predetermined food form, the composition base material is sieved and quantitatively packaged to obtain powder; or the composition base material is directly compressed into tablets to obtain tablets; or the composition base material is quantitatively filled into hard capsule shells to obtain hard capsules.

9. A method for preparing a skin-moisturizing and barrier-maintaining composition containing S-estrol, reduced coenzyme Q10, and ceramide according to claim 8, characterized in that, When preparing the reduced coenzyme Q10-complex matrix premix in B2, first add 40-50% of the total mass of the lipid complex matrix to the jacketed sealed mixing container, preheat at 47-51℃ for 8-15 min, and then uniformly add all of the reduced coenzyme Q10 within 8-15 min; then divide the remaining lipid complex matrix into two portions and add them sequentially, mixing at 120-180 r / min for 8-12 min after each portion is added; after all the addition is completed, cool to 24-28℃ at a cooling rate of 0.5-1.0℃ / min under continuous nitrogen protection and stirring at 80-120 r / min.

10. A method of preparing a composition containing S-equol, reduced coenzyme Q10 and ceramide for skin moisturizing and barrier maintenance according to claim 8, characterized in that, In B4, when preparing powder, the composition base material is passed through a 30-50 mesh sieve and then quantitatively dispensed with nitrogen; when preparing tablets, the composition base material is equilibrated at 20-25℃ for 30-60 minutes and then directly compressed into tablets, with a single-punch compression force of 6-14 kN; when preparing hard capsules, the composition base material is passed through a 30-50 mesh sieve and then filled into gelatin hard capsule shells or hydroxypropyl methylcellulose hard capsule shells, and then sealed and packaged after filling.